MyelofibrosisPhase 1NCT07708272
QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
A Phase 1 study testing TQ05105 tablets and Moxifloxacin Hydrochloride Tablets in people with Myelofibrosis, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. at 1 site in China.
Trial summary
Primary Objective: To evaluate the effect of single-dose TQ05105 on QTcF interval in healthy Chinese participants. Secondary Objectives: To evaluate the effects of single-dose TQ05105 on other cardiac parameters (heart rate, QT, RR, PR and QRS intervals) in healthy Chinese participants; To verify assay sensitivity by… Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Myelofibrosis
- What is being tested?
- TQ05105 tablets and Moxifloxacin Hydrochloride Tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 30 Jul 2026to Feb 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Voluntarily participate in the clinical trial and sign the informed consent form; fully understand the trial content, procedures and potential adverse reactions; able to communicate well with the investigator and complete the study in accordance with the protocol requirements;
- Participants (including their partners) have no plans for pregnancy, sperm donation or egg donation from screening until 6 months after the last dose of study drug, and voluntarily adopt effective contraceptive measures;
- Healthy participants aged 18 to 45 years (inclusive) at the time of signing the informed consent form, both male and female eligible;
- At screening, male participants weigh no less than 50.0 kg and female participants weigh no less than 45.0 kg. Body mass index (BMI) = weight (kg) / height² (m²), within the range of 18.0 to 26.0 kg/m² (inclusive).
Who cannot join
- History of severe or chronic diseases of the circulatory, digestive, respiratory, urinary, nervous, hematological, endocrine and metabolic, neoplastic, immune or psychiatric systems or any other medical conditions that may interfere with trial outcomes within the past 1 year or at present;
- History of any malignancy within 5 years before screening;
- Platelet count or absolute neutrophil count below the lower limit of the reference range in complete blood count at screening;
- Any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
- Subjects with any condition that may affect the absorption, distribution, metabolism or excretion of the study drug (e.g., inability to swallow tablets) or who have undergone gastrointestinal resection that may interfere with drug absorption, distribution, metabolism or excretion;
- Risk factors for torsades de pointes (TdP) at screening, including but not limited to the history of: syncope of unknown origin; heart failure; myocardial infarction; angina pectoris; history of various electrolyte abnormalities (potassium, sodium, chloride, calcium, magnesium, etc.); bundle branch block; atrial fibrillation, atrial flutter, atrial premature beats, ventricular premature beats, non-sustained or sustained ventricular tachycardia; bradycardia or sick sinus syndrome; personal or family history of any cardiac conduction abnormality; personal or family history of long QT syndrome (LQTS); or family history of sudden cardiac death;
Show all 23Show fewer
- Hypersensitivity to moxifloxacin or any fluoroquinolone antibacterial agents, TQ05105 or its excipients, or history of multiple allergies (e.g., allergy to two or more substances, including drug allergy history, predisposition to skin rash, eczema, urticaria, asthma, etc.);
- Use of any strong or moderate inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19 enzymes within 4 weeks before screening (see Appendix 3 for details);
- Use of any prescription drugs (including that may cause QT/QTc interval prolongation / TdP), over-the-counter drugs, Chinese herbal medicines or dietary supplements (e.g., vitamins, calcium supplements, etc.) within 4 weeks before screening;
- Participation in any drug clinical trial and exposure to any investigational product within 3 months before screening or within 5 half-lives of the drug (whichever is longer);
- Abnormal results of physical examination, vital signs, clinical laboratory tests (complete blood count, blood biochemistry, coagulation function, urinalysis), chest radiograph (PA and lateral views), or abdominal ultrasound (liver, gallbladder, pancreas, spleen and kidneys) at screening that are judged clinically significant by the investigator;
- 12-lead ECG exceeding the following thresholds at screening or baseline: PR > 200 ms, QRS > 110 ms, HR < 50 bpm or > 100 bpm, QTcF > 450 ms (for both males and females); or ECG abnormalities judged by the investigator to be clinically significant (e.g., atrioventricular block, torsades de pointes, other types of ventricular tachycardia, ventricular fibrillation and ventricular flutter, clinically significant T-wave changes, or any 12-lead ECG abnormalities that may affect the QTc interval);
- Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody;
- Glomerular filtration rate (eGFR) < 90 mL/min/1.73m² at screening;
- Average daily cigarette consumption of more than 5 cigarettes within 3 months before screening;
- History of substance abuse within 3 months before screening, or positive urine drug screen;
- Regular alcohol consumption within 3 months before screening, defined as more than 14 standard alcohol units per week (1 unit = 360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine), or positive breath alcohol test;
- Blood donation or blood loss ≥ 200 mL, or plasmapheresis within 4 weeks before screening;
- Consumption of any food or beverage containing alcohol (or positive breath alcohol test), grapefruit juice, coffee, tea, cola, or chocolate within 72 hours before dosing;
- Pregnant or lactating female participants, or positive blood pregnancy test or value above the upper limit of normal, or female participants of childbearing potential who have had unprotected sexual intercourse within 2 weeks before screening;
- Strenuous exercise (e.g., marathon, weightlifting) within 2 weeks before screening;
- Any other condition considered by the investigator to make the participant unsuitable for the trial;
- Participants unable to complete the trial due to personal reasons.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-Blind (Except Moxifloxacin), Placebo and Positive-Controlled, Four-Period Crossover Thorough QT/QTc Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
Primary Objective: To evaluate the effect of single-dose TQ05105 on QTcF interval in healthy Chinese participants.
Secondary Objectives:
To evaluate the effects of single-dose TQ05105 on other cardiac parameters (heart rate, QT, RR, PR and QRS intervals) in healthy Chinese participants; To verify assay sensitivity by evaluating the effect of moxifloxacin on QTcF interval; To evaluate the safety and tolerability of single-dose TQ05105 in healthy Chinese participants; To characterize the pharmacokinetic (PK) characteristics of TQ05105 and its metabolite (TQ12550) after single administration of TQ05105 tablets in healthy Chinese participants.
- Conditions
- Myelofibrosis
- Being tested
- TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets
- Medical subject headings
- Primary Myelofibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TQ05105 tabletsDrug
TQ05105 tablets are Janus kinase (JAK) inhibitors.
Placebo tabletsDrug
Placebo tablets contain no active substance.
Moxifloxacin Hydrochloride TabletsDrug
Moxifloxacin Hydrochloride Tablets serve as positive control drug.
| Study group | Role | What they receive |
|---|---|---|
| TQ05105 tablets 20 mg+Placebo tablets 10 mg | Experimental | 4 tablets of 5 mg TQ05105 tablets plus 2 tablets of 5 mg matching placebo tablets, delivering a total TQ05105 dose of 20 mg. Receives: Drug: TQ05105 tablets; Drug: Placebo tablets |
| TQ05105 tablets 30 mg | Experimental | 6 tablets of 5 mg TQ05105 tablets, with a total TQ05105 dose of 30 mg. Receives: Drug: TQ05105 tablets |
| Placebo tablets 30 mg | Placebo comparator | 6 tablets of 5 mg TQ05105 matching placebo tablets, with a total placebo dose of 30 mg. Receives: Drug: Placebo tablets |
| Moxifloxacin Hydrochloride tablets 0.4 g | Active comparator | 1 tablet of 0.4 g Moxifloxacin Hydrochloride Tablets, serving as an open-label positive control drug. Receives: Drug: Moxifloxacin Hydrochloride Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fridericia Placebo-Corrected Change from Baseline in QTc Interval (ΔΔQTcF)
Placebo \& baseline corrected ΔQTcF, core indicator to assess drug effect on ventricular repolarization.
Measured: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Secondary outcomes (15)
Heart Rate (HR)
Holter-derived heart rate
Measured: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
PR interval (PR)
PR interval obtained via continuous Holter ECG monitoring
Measured: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
RR interval (RR)
Holter-recorded RR interval
Measured: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Peak concentration (Cmax)
Maximum plasma drug concentration
Measured: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Area under the plasma concentration-time curve ( AUC0-t)
The area enclosed by the blood concentration curve to the timeline
Measured: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Plasma clearance (CL/F)
How much of the plasma is cleared per unit of time
Measured: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Plasma elimination half-life (t1/2)
The time it takes for the terminal phase blood concentration to drop by half
Measured: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Adverse event rate
The occurrence of all adverse events (AEs), and serious adverse events (SAEs).
Measured: 26 days after the first dose
Hematology
Abnormal hematology
Measured: 26 days after the first dose
Serum biochemistry
Abnormal serum biochemistry
Measured: 26 days after the first dose
Coagulation
Abnormal coagulation
Measured: 26 days after the first dose
Urinalysis
Abnormal urinalysis
Measured: 26 days after the first dose
Blood pressure
Abnormal blood pressure
Measured: 26 days after the first dose
Pulse
Abnormal pulse
Measured: 26 days after the first dose
Body temperature
Abnormal body temperature
Measured: 26 days after the first dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start30 Jul 2026
- Primary completionDec 2026 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyelofibrosisStudies of the same condition, open and under way.
- More trials run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07708272
- Sponsor's protocol ID
- TQ05105-I-10
- Status last verified
- Aug 2026
- First submitted
- 13 Jul 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind (Except Moxifloxacin), Placebo and Positive-Controlled, Four-Period Crossover Thorough QT/QTc Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
- ClinicalTrials.gov ID
- NCT07708272
- Acronym / sponsor ID
- TQ05105-I-10
- Conditions
- Myelofibrosis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 30 Jul 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary Objective: To evaluate the effect of single-dose TQ05105 on QTcF interval in healthy Chinese participants.
Secondary Objectives:
To evaluate the effects of single-dose TQ05105 on other cardiac parameters (heart rate, QT, RR, PR and QRS intervals) in healthy Chinese participants; To verify assay sensitivity by evaluating the effect of moxifloxacin on QTcF interval; To evaluate the safety and tolerability of single-dose TQ05105 in healthy Chinese participants; To characterize the pharmacokinetic (PK) characteristics of TQ05105 and its metabolite (TQ12550) after single administration of TQ05105 tablets in healthy Chinese participants.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| TQ05105 tablets 20 mg+Placebo tablets 10 mg | Experimental | Drug: TQ05105 tablets, Drug: Placebo tablets4 tablets of 5 mg TQ05105 tablets plus 2 tablets of 5 mg matching placebo tablets, delivering a total TQ05105 dose of 20 mg. |
| TQ05105 tablets 30 mg | Experimental | Drug: TQ05105 tablets6 tablets of 5 mg TQ05105 tablets, with a total TQ05105 dose of 30 mg. |
| Placebo tablets 30 mg | Placebo comparator | Drug: Placebo tablets6 tablets of 5 mg TQ05105 matching placebo tablets, with a total placebo dose of 30 mg. |
| Moxifloxacin Hydrochloride tablets 0.4 g | Active comparator | Drug: Moxifloxacin Hydrochloride Tablets1 tablet of 0.4 g Moxifloxacin Hydrochloride Tablets, serving as an open-label positive control drug. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Voluntarily participate in the clinical trial and sign the informed consent form; fully understand the trial content, procedures and potential adverse reactions; able to communicate well with the investigator and complete the study in accordance with the protocol requirements;
- Participants (including their partners) have no plans for pregnancy, sperm donation or egg donation from screening until 6 months after the last dose of study drug, and voluntarily adopt effective contraceptive measures;
- Healthy participants aged 18 to 45 years (inclusive) at the time of signing the informed consent form, both male and female eligible;
- At screening, male participants weigh no less than 50.0 kg and female participants weigh no less than 45.0 kg. Body mass index (BMI) = weight (kg) / height² (m²), within the range of 18.0 to 26.0 kg/m² (inclusive).
Key exclusion criteria (23 listed)
- History of severe or chronic diseases of the circulatory, digestive, respiratory, urinary, nervous, hematological, endocrine and metabolic, neoplastic, immune or psychiatric systems or any other medical conditions that may interfere with trial outcomes within the past 1 year or at present;
- History of any malignancy within 5 years before screening;
- Platelet count or absolute neutrophil count below the lower limit of the reference range in complete blood count at screening;
- Any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
- Subjects with any condition that may affect the absorption, distribution, metabolism or excretion of the study drug (e.g., inability to swallow tablets) or who have undergone gastrointestinal resection that may interfere with drug absorption, distribution, metabolism or excretion;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TQ05105 tabletsTQ05105 tablets are Janus kinase (JAK) inhibitors. | Drug | TQ05105 tablets 20 mg+Placebo tablets 10 mg, TQ05105 tablets 30 mg |
| Placebo tabletsPlacebo tablets contain no active substance. | Drug | Placebo tablets 30 mg, TQ05105 tablets 20 mg+Placebo tablets 10 mg |
| Moxifloxacin Hydrochloride TabletsMoxifloxacin Hydrochloride Tablets serve as positive control drug. | Drug | Moxifloxacin Hydrochloride tablets 0.4 g |
Primary outcome
Fridericia Placebo-Corrected Change from Baseline in QTc Interval (ΔΔQTcF)
Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Placebo \& baseline corrected ΔQTcF, core indicator to assess drug effect on ventricular repolarization.
15 secondary outcomes
Heart Rate (HR)
Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
PR interval (PR)
Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
RR interval (RR)
Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Peak concentration (Cmax)
Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Area under the plasma concentration-time curve ( AUC0-t)
Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Plasma clearance (CL/F)
Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Plasma elimination half-life (t1/2)
Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.
Adverse event rate
Time frame: 26 days after the first dose
Hematology
Time frame: 26 days after the first dose
Serum biochemistry
Time frame: 26 days after the first dose
Coagulation
Time frame: 26 days after the first dose
Urinalysis
Time frame: 26 days after the first dose
Blood pressure
Time frame: 26 days after the first dose
Pulse
Time frame: 26 days after the first dose
Body temperature
Time frame: 26 days after the first dose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
Related trials for Myelofibrosis
RecruitingPhase 1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Recruiting
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Myeloproliferative Neoplasm, Polycythemia Vera
RecruitingPhase 1
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Polycythemia Vera (PV), Myelofibrosis (MF)
Not yet recruiting
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Myelofibrosis, Primary Myelofibrosis (PMF)
RecruitingObservational study
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Chronic Myeloproliferative Disorders, Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing TQ05105 tablets and Moxifloxacin Hydrochloride Tablets in people with Myelofibrosis, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fridericia Placebo-Corrected Change from Baseline in QTc Interval (ΔΔQTcF) (time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.